{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T10:43:44Z","timestamp":1781174624632,"version":"3.54.1"},"reference-count":80,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T00:00:00Z","timestamp":1646784000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Multiple Myeloma (MM) is a hematologic malignancy characterized by a wide clinical and biological heterogeneity leading to different patient outcomes. Various prognostic tools to stratify newly diagnosed (ND)MM patients into different risk groups have been proposed. At baseline, the standard-of-care prognostic score is the Revised International Staging System (R-ISS), which stratifies patients according to widely available serum markers (i.e., albumin, \u03b2 2-microglobulin, lactate dehydrogenase) and high-risk cytogenetic abnormalities detected by fluorescence <jats:italic>in situ<\/jats:italic> hybridization. Though this score clearly identifies a low-risk and a high-risk population, the majority of patients are categorized as at \u201cintermediate risk\u201d. Although new prognostic factors identified through molecular assays (e.g., gene expression profiling, next-generation sequencing) are now available and may improve risk stratification, the majority of them need specialized centers and bioinformatic expertise that may preclude their broad application in the real-world setting. In the last years, new tools to monitor response and measurable residual disease (MRD) with very high sensitivity after the start of treatment have been developed. MRD analyses both inside and outside the bone marrow have a strong prognostic impact, and the achievement of MRD negativity may counterbalance the high-risk behavior identified at baseline. All these techniques have been developed in clinical trials. However, their efficient application in real-world clinical practice and their potential role to guide treatment-decision making are still open issues. This mini review will cover currently known prognostic factors identified before and during first-line treatment, with a particular focus on their potential applications in real-world clinical practice.<\/jats:p>","DOI":"10.3389\/fonc.2022.830922","type":"journal-article","created":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T05:35:15Z","timestamp":1646804115000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":23,"title":["Risk Stratification Before and During Treatment in Newly Diagnosed Multiple Myeloma: From Clinical Trials to the Real-World Setting"],"prefix":"10.3389","volume":"12","author":[{"given":"Francesca","family":"Bonello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Cani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"D\u2019Agostino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group Updated Criteria for the Diagnosis of Multiple Myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70143-7","article-title":"Multiple Myeloma and the Road to Personalised Medicine","volume":"12","author":"Russell","year":"2011","journal-title":"Lancet Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.91","article-title":"Characteristics of Exceptional Responders to Lenalidomidebased Therapy in Multiple Myeloma","volume":"5","author":"Vu","year":"2015","journal-title":"Blood Cancer J"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","article-title":"A Clinical Staging System for Multiple Myeloma Correlation of Measured Myeloma Cell Mass With Presenting Clinical Features, Response to Treatment, and Survival","volume":"36","author":"Durie","year":"1975","journal-title":"Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1001\/jamaoncol.2016.3160","article-title":"Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-Analysis","volume":"3","author":"Munshi","year":"2017","journal-title":"JAMA Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002827","article-title":"A Large Meta-Analysis Establishes the Role of MRD Negativity in Long-Term Survival Outcomes in Patients With Multiple Myeloma","volume":"4","author":"Munshi","year":"2020","journal-title":"Blood Adv"},{"key":"B7","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1182\/blood.2020010439","article-title":"Sustained Minimal Residual Disease Negativity With Daratumumab in Newly Diagnosed Multiple Myeloma: MAIA and ALCYONE","volume":"139","author":"San-Miguel","year":"2021","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2008.180","article-title":"Impact of Early Relapse After Auto-SCT for Multiple Myeloma","volume":"42","author":"Kumar","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2014.237","article-title":"Early Relapse After Single Auto-SCT for Multiple Myeloma Is a Major Predictor of Survival in the Era of Novel Agents","volume":"50","author":"Jimenez-Zepeda","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04355.x","article-title":"Criteria for the Classification of Monoclonal Gammopathies, Multiple Myeloma and Related Disorders: A Report of the International Myeloma Working Group","volume":"121","author":"Kyle","year":"2003","journal-title":"Br J Haematol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41408-020-00366-3","article-title":"International Myeloma Working Group Risk Stratification Model for Smoldering Multiple Myeloma (SMM)","volume":"10","author":"Mateos","year":"2020","journal-title":"Blood Cancer J"},{"key":"B13","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41408-018-0077-4","article-title":"Risk Stratification of Smoldering Multiple Myeloma Incorporating Revised IMWG Diagnostic Criteria","volume":"8","author":"Lakshman","year":"2018","journal-title":"Blood Cancer J"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30309-2","article-title":"International Myeloma Working Group Consensus Recommendations on Imaging in Monoclonal Plasma Cell Disorders","volume":"20","author":"Hillengass","year":"2019","journal-title":"Lancet Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.291","article-title":"18f-FDG PET\/CT Focal, But Not Osteolytic, Lesions Predict the Progression of Smoldering Myeloma to Active Disease","volume":"30","author":"Zamagni","year":"2016","journal-title":"Leukemia"},{"key":"B16","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41467-020-20524-2","article-title":"The Molecular Make Up of Smoldering Myeloma Highlights the Evolutionary Pathways Leading to Multiple Myeloma","volume":"12","author":"Boyle","year":"2021","journal-title":"Nat Commun"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00437","article-title":"Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression","volume":"38","author":"Bustoros","year":"2020","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.242","article-title":"International Staging System for Multiple Myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.247","article-title":"IMWG Consensus on Risk Stratification in Multiple Myeloma","volume":"28","author":"Chng","year":"2014","journal-title":"Leukemia"},{"key":"B20","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41408-020-0307-4","article-title":"Clinical Features and Survival of Multiple Myeloma Patients Harboring T(14;16) in the Era of Novel Agents","volume":"10","author":"Mina","year":"2020","journal-title":"Blood Cancer J"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.278888","article-title":"Chromosome 1q21 Abnormalities Refine Outcome Prediction in Patients With Multiple Myeloma - A Meta-Analysis of 2,596 Trial Patients","volume":"106","author":"Weinhold","year":"2021","journal-title":"Haematologica"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-137021","article-title":"A New Risk Stratification Model (R2-ISS) in Newly Diagnosed Multiple Myeloma: Analysis of Mature Data From 7077 Patients Collected By European Myeloma Network Within HARMONY Big Data Platform","volume":"136","author":"D\u2019Agostino","year":"2020","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41408-019-0254-0","article-title":"Gain of Chromosome 1q Is Associated With Early Progression in Multiple Myeloma Patients Treated With Lenalidomide, Bortezomib, and Dexamethasone","volume":"9","author":"Schmidt","year":"2019","journal-title":"Blood Cancer J"},{"key":"B24","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1182\/blood-2020-137060","article-title":"Impact of Gain and Amplification of 1q in Newly Diagnosed Multiple Myeloma Patients Receiving Carfilzomib-Based Treatment in the FORTE Trial","volume":"136","author":"D\u2019Agostino","year":"2020","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1038\/s41467-019-09555-6","article-title":"Multiple Myeloma Immunoglobulin Lambda Translocations Portend Poor Prognosis","volume":"10","author":"Barwick","year":"2019","journal-title":"Nat Commun"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-20-0951","article-title":"Early Relapse Risk in Patients With Newly Diagnosed Multiple Myeloma Characterized by Next-Generation Sequencing","volume":"26","author":"D\u2019Agostino","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.179","article-title":"Prediction of Outcome in Newly Diagnosed Myeloma: A Meta-Analysis of the Molecular Profiles of 1905 Trial Patients","volume":"32","author":"Shah","year":"2018","journal-title":"Leukemia"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008346","article-title":"Del(17p) Without TP53 Mutation Confers a Poor Prognosis in Intensively Treated Newly Diagnosed Patients With Multiple Myeloma","volume":"137","author":"Corre","year":"2021","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2017.06.020","article-title":"Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma","volume":"17","author":"van Beers","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002838","article-title":"Prognostic and Predictive Performance of R-ISS With SKY92 in Older Patients With Multiple Myeloma: The HOVON-87\/NMSG-18 Trial","volume":"4","author":"Kuiper","year":"2020","journal-title":"Blood Adv"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD-2007-10-119321","article-title":"High-Risk Myeloma: A Gene Expression Based Risk-Stratification Model for Newly Diagnosed Multiple Myeloma Treated With High-Dose Therapy Is Predictive of Outcome in Relapsed Disease Treated With Single-Agent Bortezomib or High-Dose Dexamethasone","volume":"111","author":"Zhan","year":"2008","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/S41375-020-0750-Z","article-title":"Predicting Ultrahigh Risk Multiple Myeloma by Molecular Profiling: An Analysis of Newly Diagnosed Transplant Eligible Myeloma XI Trial Patients","volume":"34","author":"Shah","year":"2020","journal-title":"Leukemia"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-046225","article-title":"MUK Nine OPTIMUM Protocol: A Screening Study to Identify High-Risk Patients With Multiple Myeloma Suitable for Novel Treatment Approaches Combined With a Phase II Study Evaluating Optimised Combination of Biological Therapy in Newly Diagnosed High-Risk Mu","volume":"11","author":"Brown","year":"2021","journal-title":"BMJ Open"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2013.01.019","article-title":"Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013","volume":"88","author":"Mikhael","year":"2013","journal-title":"Mayo Clin Proc"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-05-1858","article-title":"Circulating Plasma Cells Detected by Flow Cytometry as a Predictor of Survival in 302 Patients With Newly Diagnosed Multiple Myeloma","volume":"106","author":"Nowakowski","year":"2005","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD-2020-137075","article-title":"Poor Prognosis of Multiple Myeloma Predicted By High Levels of Circulating Plasma Cells Is Independent From Other High-Risk Features But Is Modulated By the Achievement of Minimal Residual Disease Negativity","volume":"136","author":"Bertamini","year":"2020","journal-title":"Blood"},{"key":"B37","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1182\/blood-2018-04-842880","article-title":"The Presence of Large Focal Lesions Is a Strong Independent Prognostic Factor in Multiple Myeloma","volume":"132","author":"Rasche","year":"2018","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41375-019-0660-0","article-title":"Extramedullary Multiple Myeloma","volume":"34","author":"Bhutani","year":"2020","journal-title":"Leukemia"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-017-00296-y","article-title":"Spatial Genomic Heterogeneity in Multiple Myeloma Revealed by Multi-Region Sequencing","volume":"8","author":"Rasche","year":"2017","journal-title":"Nat Commun"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.099358","article-title":"European Myeloma Network Recommendations on the Evaluation and Treatment of Newly Diagnosed Patients With Multiple Myeloma","volume":"99","author":"Engelhardt","year":"2014","journal-title":"Haematologica"},{"key":"B41","doi-asserted-by":"publisher","first-page":"101929","DOI":"10.1016\/J.CTRV.2019.101929","article-title":"Multiple Myeloma: Role of Autologous Transplantation","volume":"82","author":"Ntanasis-Stathopoulos","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1002\/CNCR.33825","article-title":"\u201cI Took the Road Less Traveled, and That has Made All the Difference\u201d: Making a Case for High-Dose Therapy and Autologous Stem Cell Transplantation in Elderly Patients With Newly Diagnosed Multiple Myeloma","volume":"127","author":"Nooka","year":"2021","journal-title":"Cancer"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1002\/CNCR.33831","article-title":"Outcomes of Upfront Autologous Hematopoietic Cell Transplantation in Patients With Multiple Myeloma Who Are 75 Years Old or Older","volume":"127","author":"Munshi","year":"2021","journal-title":"Cancer"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/J.BBMT.2017.06.014","article-title":"Hematopoietic Cell Transplantation-Specific Comorbidity Index Predicts Morbidity and Mortality in Autologous Stem Cell Transplantation","volume":"23","author":"Berro","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric Assessment Predicts Survival and Toxicities in Elderly Myeloma Patients: An International Myeloma Working Group Report","volume":"125","author":"Palumbo","year":"2015","journal-title":"Blood"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.162693","article-title":"A Concise Revised Myeloma Comorbidity Index as a Valid Prognostic Instrument in a Large Cohort of 801 Multiple Myeloma Patients","volume":"102","author":"Engelhardt","year":"2017","journal-title":"Haematologica"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0539-0","article-title":"A Simplified Frailty Scale Predicts Outcomes in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma Treated in the FIRST (MM-020) Trial","volume":"34","author":"Facon","year":"2020","journal-title":"Leukemia"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(18)30220-5","article-title":"A Clinical Prediction Model for Outcome and Therapy Delivery in Transplant-Ineligible Patients With Myeloma (UK Myeloma Research Alliance Risk Profile): A Development and Validation Study","volume":"6","author":"Cook","year":"2019","journal-title":"Lancet Haematol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0918-6","article-title":"Defining the Vulnerable Patient With Myeloma\u2014A Frailty Position Paper of the European Myeloma Network","volume":"34","author":"Cook","year":"2020","journal-title":"Leukemia"},{"key":"B50","doi-asserted-by":"publisher","first-page":"Abstract 1889","DOI":"10.1182\/blood-2018-99-116920","article-title":"Geriatric Impairments and Low Muscle Mass Are Associated With Treatment Discontinuation and Overall Survival in Newly Diagnosed Non-Transplant Eligible Multiple Myeloma Patients (nte-NDMM) Treated With Dose-Adjusted Melphalan-Prednisone-Bortezomib (MPV) \u2014 Results of the Dutch HOVON 123 Study","volume":"132","author":"Stege","year":"2018","journal-title":"Blood"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0142-9","article-title":"Patient-Centered Practice in Elderly Myeloma Patients: An Overview and Consensus From the European Myeloma Network (EMN)","volume":"32","author":"Larocca","year":"2018","journal-title":"Leukemia"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)62167-9","article-title":"Frailty in Elderly People","volume":"381","author":"Clegg","year":"2013","journal-title":"Lancet"},{"key":"B53","doi-asserted-by":"publisher","first-page":"3106","DOI":"10.3390\/cancers12113106","article-title":"Diagnostic and Therapeutic Challenges in the Management of Intermediate and Frail Elderly Multiple Myeloma Patients","volume":"12","author":"Bonello","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B54","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41408-021-00464-w","article-title":"Octogenarian Newly Diagnosed Multiple Myeloma Patients Without Geriatric Impairments: The Role of Age >80 in the IMWG Frailty Score","volume":"11","author":"D\u2019Agostino","year":"2021","journal-title":"Blood Cancer J"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group Consensus Criteria for Response and Minimal Residual Disease Assessment in Multiple Myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00001","article-title":"Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma","volume":"10","author":"Oliva","year":"2020","journal-title":"Front Oncol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-021-00633-5","article-title":"MRD Assessment in Multiple Myeloma: Progress and Challenges","volume":"16","author":"Bertamini","year":"2021","journal-title":"Curr Hematol Malig Rep"},{"key":"B58","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/cyto.b.21265","article-title":"Immunophenotype of Normal vs. Myeloma Plasma Cells: Toward Antibody Panel Specifications for MRD Detection in Multiple Myeloma","volume":"90","author":"Flores-Montero","year":"2016","journal-title":"Cytometry B Clin Cytom"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1200\/edbk_159088","article-title":"Minimal Residual Disease by Next-Generation Sequencing: Pros and Cons","volume":"35","author":"Avet-Loiseau","year":"2016","journal-title":"Am Soc Clin Oncol Educ B"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0508-7","article-title":"Next-Generation Sequencing of Immunoglobulin Gene Rearrangements for Clonality Assessment: A Technical Feasibility Study by EuroClonality-NGS","volume":"33","author":"Scheijen","year":"2019","journal-title":"Leukemia"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0499-4","article-title":"Quality Control and Quantification in IG\/TR Next-Generation Sequencing Marker Identification: Protocols and Bioinformatic Functionalities by EuroClonality-NGS","volume":"33","author":"Knecht","year":"2019","journal-title":"Leukemia"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.58","article-title":"Analytical and Clinical Validation of a Novel in-House Deep-Sequencing Method for Minimal Residual Disease Monitoring in a Phase II Trial for Multiple Myeloma","volume":"31","author":"Martinez-Lopez","year":"2017","journal-title":"Leukemia"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2018.10.008","article-title":"Establishment of Immunoglobulin Heavy (IGH) Chain Clonality Testing by Next-Generation Sequencing for Routine Characterization of B-Cell and Plasma Cell Neoplasms","volume":"21","author":"Arcila","year":"2019","journal-title":"J Mol Diagnostics"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01231","article-title":"Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma","volume":"38","author":"Paiva","year":"2020","journal-title":"J Clin Oncol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-137351","article-title":"Impact of Minimal Residual Disease (MRD) By Multiparameter Flow Cytometry (MFC) and Next-Generation Sequencing (NGS) on Outcome: Results of Newly Diagnosed Transplant-Eligible Multiple Myeloma (MM) Patients Enrolled in the Forte Trial","volume":"136","author":"Oliva","year":"2020","journal-title":"Blood"},{"key":"B66","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41408-021-00498-0","article-title":"Minimal Residual Disease Assessment by Multiparameter Flow Cytometry in Transplant-Eligible Myeloma in the EMN02\/HOVON 95 MM Trial","volume":"11","author":"Oliva","year":"2021","journal-title":"Blood Cancer J"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-06-858613","article-title":"Minimal Residual Disease Negativity Using Deep Sequencing Is a Major Prognostic Factor in Multiple Myeloma","volume":"132","author":"Perrot","year":"2018","journal-title":"Blood"},{"key":"B68","doi-asserted-by":"publisher","first-page":"Abstract e19280","DOI":"10.1200\/jco.2020.38.15_suppl.e19280","article-title":"Real-World Sustained Minimal Residual Disease (MRD) Negativity Using NGS in Multiple Myeloma","volume":"38","author":"Demaree","year":"2020","journal-title":"J Clin Oncol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3390\/DIAGNOSTICS11101872","article-title":"Harmonization of Flow Cytometric Minimal Residual Disease Assessment in Multiple Myeloma in Centers of Polish Myeloma Consortium","volume":"11","author":"Krzywdzi\u0144ska","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"B70","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.3390\/cancers11122015","article-title":"Pursuing a Curative Approach in Multiple Myeloma: A Review of New Therapeutic Strategies","volume":"11","author":"D\u2019Agostino","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B71","first-page":"60","article-title":"MRD Evaluation By PET\/CT According To Deauville Criteria Combined With Bone Marrow Techniques In Newly Diagnosed Transplant Eligible Multiple Myeloma Patients Enrolled In The Phase II FORTE Trial","volume":"4","author":"Zamagni","year":"2020","journal-title":"HemaSphere"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.00386","article-title":"Standardization of 18 F-FDG\u2013PET\/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma","volume":"39","author":"Zamagni","year":"2021","journal-title":"J Clin Oncol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1148\/radiol.2019181949","article-title":"Guidelines for Acquisition, Interpretation, and Reporting of Whole-Body MRI in Myeloma: Myeloma Response Assessment and Diagnosis System (MY-RADS)","volume":"291","author":"Messiou","year":"2019","journal-title":"Radiology"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1002\/CAM4.4136","article-title":"Predictive Role of Diffusion-Weighted Whole-Body MRI (DW-MRI) Imaging Response According to MY-RADS Criteria After Autologous Stem Cell Transplantation in Patients With Multiple Myeloma and Combined Evaluation With MRD Assessment by Flow Cytometry","volume":"10","author":"Belotti","year":"2021","journal-title":"Cancer Med"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019002610","article-title":"Blood Monitoring of Circulating Tumor Plasma Cells by Next Generation Flow in Multiple Myeloma After Therapy","volume":"134","author":"Sanoja-Flores","year":"2019","journal-title":"Blood"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018025197","article-title":"Myeloma MRD by Deep Sequencing From Circulating Tumor DNA Does Not Correlate With Results Obtained in the Bone Marrow","volume":"2","author":"Mazzotti","year":"2018","journal-title":"Blood Adv"},{"key":"B77","doi-asserted-by":"publisher","first-page":"Abstract 8010","DOI":"10.1200\/JCO.2021.39.15_suppl.8010","article-title":"Analysis of Minimal Residual Disease in Bone Marrow by NGF and in Peripheral Blood by Mass Spectrometry in Newly Diagnosed Multiple Myeloma Patients Enrolled in the GEM2012MENOS65 Clinical Trial","volume":"39","author":"Puig","year":"2021","journal-title":"J Clin Oncol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.8512","article-title":"Analysis of Treatment Efficacy in the GEM-CESAR Trial for High-Risk Smoldering Multiple Myeloma Patients: Comparison Between the Standard and IMWG MRD Criteria and QIP-MS Including FLC (QIP-FLC-Ms)","volume":"38","author":"Pu\u00edg","year":"2020","journal-title":"J Clin Oncol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41408-021-00408-4","article-title":"Mass Spectrometry for the Evaluation of Monoclonal Proteins in Multiple Myeloma and Related Disorders\u202f: An International Myeloma Working Group Mass Spectrometry Committee Report","volume":"11","author":"Murray","year":"2021","journal-title":"Blood Cancer J"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000519","article-title":"Minimal Residual Disease in Multiple Myeloma: Ready for Prime Time","volume":"27","author":"Mina","year":"2021","journal-title":"Cancer J (United States)"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.830922\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T05:35:18Z","timestamp":1646804118000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.830922\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,9]]},"references-count":80,"alternative-id":["10.3389\/fonc.2022.830922"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.830922","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,9]]},"article-number":"830922"}}